Seoulin Bioscience Co.Ltd (038070) — Capital Reinvestment Ratio
Latest as of December 2025:
0.02x
Seoulin Bioscience Co.Ltd (038070) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow (₩631.76 Million) in capital expenditures (₩10.90 Million). See 038070 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.02x
Capex / Operating Cash Flow
Operating Cash Flow
₩631.76 Million
KRW
Capital Expenditures
₩10.90 Million
KRW
Data as of
Dec 2025
Most recent filing
Seoulin Bioscience Co.Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks Seoulin Bioscience Co.Ltd's Capital Reinvestment Ratio across 11 annual periods.
Annual Capital Reinvestment Ratio for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for Seoulin Bioscience Co.Ltd from 2013 to 2025. For live market cap and broader valuation context, see market value of Seoulin Bioscience Co.Ltd.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | ₩4.76 Billion | ₩507.47 Million | ▼ -89.8% |
| 2023 | 1.05x | ₩930.57 Million | ₩974.21 Million | ▲ +459.1% |
| 2021 | 0.19x | ₩8.92 Billion | ₩1.67 Billion | ▲ +71.9% |
| 2020 | 0.11x | ₩3.68 Billion | ₩401.34 Million | ▲ +196.1% |
| 2019 | 0.04x | ₩7.32 Billion | ₩269.29 Million | ▼ -62.4% |
| 2018 | 0.10x | ₩4.17 Billion | ₩408.02 Million | ▼ -98.5% |
| 2017 | 6.71x | ₩1.30 Billion | ₩8.73 Billion | ▲ +156.1% |
| 2016 | 2.62x | ₩2.76 Billion | ₩7.21 Billion | ▲ +188.0% |
| 2015 | 0.91x | ₩4.12 Billion | ₩3.74 Billion | ▲ +227.0% |
| 2014 | 0.28x | ₩2.74 Billion | ₩761.57 Million | ▲ +2367.3% |
| 2013 | 0.01x | ₩4.94 Billion | ₩55.65 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow